Preferred Label : Cinacalcet;
MeSH definition : A naphthalene derivative and CALCIMIMETIC AGENT that increases the sensitivity of
PARATHYROID GLAND calcium-sensing receptors to serum calcium. This action reduces
parathyroid hormone secretion and decreases serum calcium in the treatment of PARATHYROID
DISEASES.;
CISMeF synonym : 073, AMG; 1493, KRN;
MeSH Hyperonym : cinacalcet;
MeSH hyponym : sensipar; AMG 073; Alpha-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphaR)-hydrochloride; KRN 1493; AMG073;
MeSH Related Number : 1K860WSG25;364782-34-3 (cinacalcet); 1K860WSG25;
Registry Number MeSH : 1K860WSG25;
Wikipedia link : https://en.wikipedia.org/wiki/Cinacalcet;
Is substance : O;
UNII : UAZ6V7728S;
Origin ID : D000069449;
UMLS CUI : C1337242;
ATC code(s)
Allowable qualifiers
Pharmacological action(s)
Record concept(s)
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
A naphthalene derivative and CALCIMIMETIC AGENT that increases the sensitivity of
PARATHYROID GLAND calcium-sensing receptors to serum calcium. This action reduces
parathyroid hormone secretion and decreases serum calcium in the treatment of PARATHYROID
DISEASES.
https://www.ema.europa.eu/en/medicines/human/EPAR/cinacalcet-accordpharma
2020
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
Cinacalcet
treatment outcome
drug approval
europe
drugs, generic
cinacalcet
hypercalcemia
parathyroid diseases
hyperparathyroidism, secondary
adult
child
administration, oral
Calcium-Regulating Hormones and Agents
Calcium-Regulating Hormones and Agents
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Cinacalcet
---
http://www.has-sante.fr/portail/jcms/c_750917/mimpara
http://www.has-sante.fr/portail/jcms/c_783514/synthese-d-avis-mimpara-ct6202
http://www.has-sante.fr/portail/upload/docs/application/pdf/2009-02/mimpara_-_ct-_6202.pdf
http://www.has-sante.fr/portail/upload/docs/application/pdf/2010-11/mimpara_ct_6202.pdf
http://www.has-sante.fr/portail/jcms/c_400628/mimpara-30-mg-comprime-pellicule-1-plaquette-de-14-comprimes-cip-365-154-8-2-plaquettes-de-14-comprimes-cip-365-155-4-6-plaquettes-de-14-comprimes-cip-365-156-0-1-flacon-de-30-comprimes-cip-365-157-7-mimpara-60-mg-comprime-pellicule-1-plaquette-de-14-comprimes-cip-365-158-3-2-plaquettes-de-14-comprimes-cip-365-160-8-6-plaquettes-de-14-comprimes-cip-365-161-4-1-flacon-de-30-comprimes-cip-365-162-0-mimpara-90-mg-comprime-pellicule-1-plaquette-de-14-comprimes-cip-365-163-7-2-plaquettes-de-14-comprimes-cip-365-164-3-6-plaquettes-de-14-comprimes-cip-365-166-6-1-flacon-de-30-comprimes-cip-365-167-2
false
France
French
Cinacalcet
Cinacalcet
evaluation of the transparency committee
cinacalcet
hyperparathyroidism, primary
administration, oral
calcimimetic agents
calcimimetic agents
hypercalcemia
parathyroid neoplasms
hyperparathyroidism, secondary
renal insufficiency, chronic
insurance, health, reimbursement
renal dialysis
adult
aged
guidelines for drug use
treatment outcome
clinical trials as topic
hypercalcemia
---
https://www.ema.europa.eu/medicines/human/EPAR/Cinacalcet-Mylan
2015
false
United Kingdom
French
English
syndication feed
drugs, generic
Cinacalcet
Cinacalcet
cinacalcet
hyperparathyroidism, secondary
hypercalcemia
treatment outcome
drug evaluation
drug approval
drug labeling
tablets
administration, oral
adult
aged
parathyroid neoplasms
renal insufficiency, chronic
drug interactions
pregnancy
drug evaluation
summary of product characteristics
package leaflet
hyperparathyroidism, primary
---
http://www.has-sante.fr/portail/jcms/c_1743362/fr/mimpara
2014
false
false
false
France
French
administration, oral
insurance, health, reimbursement
treatment outcome
cinacalcet
calcimimetic agents
hypercalcemia
renal dialysis
hyperparathyroidism, secondary
parathyroid neoplasms
hyperparathyroidism, primary
kidney failure, chronic
Cinacalcet
---
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/36267a-fra.php
2013
false
Canada
French
English
Cardiotoxicity
Cinacalcet
heart rate
hypocalcemia
cinacalcet
long qt syndrome
risk factors
pharmacovigilance note
patient education handout
---
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/25849a-fra.php
https://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/25849a-eng.php
2013
false
Canada
French
English
Cinacalcet
child
pregnancy
breast feeding
pharmacovigilance note
cinacalcet
parathyroid diseases
Product containing cinacalcet (medicinal product)
Contraindications, Drug
---
https://www.ema.europa.eu/medicines/human/EPAR/Mimpara
2012
false
United Kingdom
French
English
syndication feed
Cinacalcet
Cinacalcet
cinacalcet
hyperparathyroidism, secondary
hypercalcemia
treatment outcome
drug evaluation
drug approval
drug labeling
tablets
administration, oral
adult
aged
parathyroid neoplasms
renal insufficiency, chronic
drug interactions
pregnancy
drug evaluation
summary of product characteristics
package leaflet
hyperparathyroidism, primary
---
https://www.ema.europa.eu/medicines/human/EPAR/Parareg
2009
false
United Kingdom
French
English
syndication feed
Cinacalcet
hyperparathyroidism, secondary
hypercalcemia
renal insufficiency, chronic
parathyroid neoplasms
renal dialysis
cinacalcet
drug evaluation
summary of product characteristics
package leaflet
---
https://www.revmed.ch/RMS/2008/RMS-147/Place-de-la-vitamine-D-du-sevelamer-et-du-cinacalcet-dans-la-prise-en-charge-des-patients-en-insuffisance-renale
2008
true
Switzerland
French
Cinacalcet
Sevelamer
vitamins
vitamin D
renal insufficiency
hyperparathyroidism, secondary
hyperparathyroidism, secondary
vitamin D
chelating agents
journal article
---
https://www.cadth.ca/sites/default/files/pdf/108_No62_cinacalcet_edrug_f.pdf
2004
false
Canada
French
Cinacalcet
hyperparathyroidism, secondary
clinical trials as topic
kidney diseases
chronic disease
cinacalcet
drug evaluation
---